Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
FDA approves first oral PCSK9 inhibitor for high cholesterol

FDA approves first oral PCSK9 inhibitor for high cholesterol

New Capabilities

Merck's Lipfendra brings injection-strength LDL lowering to a once-daily pill, priced below the shots

December 31st, 2029: Cardiovascular outcomes trial expected to report

Overview

For a decade, the most powerful cholesterol drugs came only as shots. On July 16, 2026, the FDA approved Merck's Lipfendra, a once-daily pill that cut LDL cholesterol about as much as those injections did.

PCSK9 inhibitors cut 'bad' cholesterol by more than half, but the needle and the price kept many patients away. Lipfendra costs $315 a month, below the $500-to-$600 injections. Whether it also prevents heart attacks and strokes won't be confirmed until a large trial reports in 2029.

Why it matters

The strongest cholesterol medicine now comes as a daily pill, cheaper than the shots. If insurers cover it, far more patients could reach it.

Questions about this story

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Higher or Lower

Key Indicators

56%
LDL-C reduction
Placebo-adjusted drop at 24 weeks in the CORALreef Lipids trial; 59% in the familial-cholesterol trial.
$315
Monthly price
About $10.50 a tablet, below the $500-to-$600 monthly cost of injectable PCSK9 drugs.
$5B
Peak annual sales estimate
Analyst projection for Lipfendra at its commercial peak.
14,500+
Outcomes trial patients
Enrollment in CORALreef Outcomes, testing whether the pill cuts heart attacks and strokes.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Log in to play. Track your picks, climb the leaderboards. Log in Sign Up
Predict 4 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play
Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play
Timeline Five events from this story — drag them oldest to newest. Log in to play
Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Dean Y. Li
Dean Y. Li
Led the program behind Merck's first-in-class approval
 Robert M. Davis
Robert M. Davis
Counting on new products as Keytruda nears patent loss

Organizations Involved

Merck & Co.
Merck & Co.
Pharmaceutical company
Developer and seller of Lipfendra

The U.S. drugmaker that developed Lipfendra and will sell it.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal agency
Reviewed and approved Lipfendra

The U.S. regulator that decides which drugs can be sold in the country.

Timeline

August 2023 December 2029

5 events Latest: December 31st, 2029
Tap a bar to jump to that date

  1. Cardiovascular outcomes trial expected to report

    Latest Trial

    CORALreef Outcomes is due to show whether the LDL drop translates into fewer heart attacks and strokes, the evidence needed to guide widespread use.

  2. FDA approves Lipfendra

    Today Approval

    The FDA clears Lipfendra (enlicitide) as the first oral PCSK9 inhibitor, for adults with high LDL cholesterol including inherited high cholesterol. Merck sets the price at $315 a month.

  3. FDA grants a priority review voucher

    Regulatory

    The FDA awards enlicitide a Commissioner's National Priority Voucher, cutting its review from roughly a year to one or two months.

  4. Phase 3 data show the pill matches the shots

    Trial

    CORALreef Lipids results show enlicitide cut LDL-C by about 56% versus placebo at 24 weeks. A separate trial in familial high cholesterol showed a 59% drop.

  5. Merck starts the CORALreef Outcomes trial

    Trial

    Merck begins testing oral enlicitide in more than 14,500 high-risk patients to see whether it prevents heart attacks and strokes. Results are due around December 2029.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

September 1987

First statin approved (1987)

The FDA approved lovastatin (Mevacor) from Merck, the first statin. It was a daily pill that lowered LDL cholesterol by blocking an enzyme the liver uses to make it. Nothing so effective and convenient had existed before.

Then

Statins spread quickly as safe, easy-to-take pills for a common problem.

Now

They became among the most-prescribed drugs in the world and are now cheap generics that anchor cholesterol care.

Why this matters now

A potent oral pill, again from Merck, is what turned cholesterol lowering into mass-scale medicine. Lipfendra aims to do the same for a class stuck behind needles.

July-August 2015

PCSK9 injections launch (2015)

The FDA approved Amgen's Repatha and Regeneron and Sanofi's Praluent, the first PCSK9 inhibitors. Both cut LDL sharply but had to be injected, and both launched near $14,000 a year. Insurers built strict prior-authorization walls.

Then

Early sales badly missed forecasts as payers blocked access and patients balked at the price.

Now

The makers later cut prices by about 60%, and outcomes trials proved the drugs reduce heart attacks, slowly widening use.

Why this matters now

This class works, but injections and price throttled it for years. Lipfendra's lower price and pill form are a direct answer to that history.

September 2019

First oral GLP-1 approved (2019)

The FDA approved Rybelsus (oral semaglutide), the first pill version of a GLP-1 drug for type 2 diabetes, a class that had been injection-only. It proved a large peptide could be formulated into a daily tablet.

Then

The pill expanded a fast-growing class to patients who resisted shots, though it required careful dosing on an empty stomach.

Now

It set the template for turning injectable biologic mechanisms into oral drugs, now a major industry race.

Why this matters now

Lipfendra is another oral take on an injection-only mechanism. Rybelsus shows both the access upside and the practical tradeoffs of moving a peptide into a pill.

Sources

(7)
+1
Merck The American Journal of Managed Care CNBC Fierce Pharma Merck Clinical Trials Pharmacy Times The American Journal of Managed Care